Definition of First-Line Endocrine Therapy for Hormone Receptor-Positive Advanced Breast Cancer Reply

被引：0
作者：
Ellis, Matthew J. [1 ]
Robertson, John F. R. [2 ]
机构：
[1] Baylor Coll Med, Houston, TX 77030 USA
[2] Univ Nottingham, Derby, England
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2016年 / 34卷 / 16期
关键词：
FULVESTRANT; 500; MG; ANASTROZOLE; TRIAL; 1ST;
D O I：
10.1200/JCO.2016.66.6727
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：1960 / +
页数：3
相关论文
共 50 条
  • [31] Adjuvant Endocrine Therapy of Perimenopausal and Recently Postmenopausal Women With Hormone Receptor-Positive Breast Cancer
    Pan, Kathy
    Chlebowski, Rowan T.
    CLINICAL BREAST CANCER, 2014, 14 (03) : 147 - 153
  • [32] A comparison of fulvestrant plus a targeted agent with fulvestrant alone in hormone receptor-positive advanced breast cancer that progressed on prior endocrine therapy: a meta-analysis
    Xu, Liang
    Yan, Ningning
    Li, Zhihua
    Luo, Lihua
    Wu, Xiaobo
    Liu, Qiuming
    Xu, Yingchun
    Cao, Yali
    ONCOTARGETS AND THERAPY, 2018, 11 : 8389 - 8398
  • [33] Tolerability of Therapies Recommended for the Treatment of Hormone Receptor-Positive Locally Advanced or Metastatic Breast Cancer
    Ohno, Shinji
    CLINICAL BREAST CANCER, 2016, 16 (04) : 238 - 246
  • [34] The therapeutic role of fulvestrant in the management of patients with hormone receptor-positive breast cancer
    Ciruelos, Eva
    Pascual, Tomas
    Arroyo Vozmediano, Maria Luisa
    Blanco, Marta
    Manso, Luis
    Parrilla, Lucia
    Munoz, Cesar
    Vega, Estela
    Jackelin Calderon, Monica
    Sancho, Blanca
    Cortes-Funes, Hernan
    BREAST, 2014, 23 (03) : 201 - 208
  • [35] Fulvestrant in management of hormone receptor-positive metastatic breast cancer
    Shafaee, Maryam Nemati
    Ellis, Matthew James
    FUTURE ONCOLOGY, 2018, 14 (18) : 1789 - 1800
  • [36] RE: "Cost-effectiveness analysis of fulvestrant versus anastrozole as first-line treatment for hormone receptor-positive advanced breast cancer," by Ding H., etal.
    Telford, Claire
    EUROPEAN JOURNAL OF CANCER CARE, 2018, 27 (02)
  • [37] Neoadjuvant endocrine therapy for estrogen receptor-positive primary breast cancer
    Yamamoto, Yutaka
    Goto-Yamaguchi, Lisa
    Takeno, Masako
    Yamamoto-Ibusuki, Mutsuko
    CHINESE CLINICAL ONCOLOGY, 2020, 9 (03) : 30
  • [38] Preferences for the sequencing of first-line systemic treatments in metastatic hormone receptor-positive, HER2-negative breast cancer
    Al Mahmasani, Layal
    Amhaz, Ghid
    Abou Zeidane, Reine
    Chamseddine, Nathalie
    Hatab, Taha
    Sabbagh, Saad
    Charafeddine, Maya
    Assi, Hazem I.
    FRONTIERS IN ONCOLOGY, 2023, 13
  • [39] Targeted Therapies Overcoming Endocrine Resistance in Hormone Receptor-Positive Breast Cancer
    Almstedt, Katrin
    Schmidt, Marcus
    BREAST CARE, 2015, 10 (03) : 168 - 172
  • [40] Endocrine therapy for hormone receptor-positive, HER2-negative metastatic breast cancer: extending endocrine sensitivity
    Frassoldati, Antonio
    Biganzoli, Laura
    Bordonaro, Roberto
    Cinieri, Saverio
    Conte, Pierfranco
    De Laurentis, Michelino
    Del Mastro, Lucia
    Gori, Stefania
    Lauria, Rossella
    Marchetti, Paolo
    Michelotti, Andrea
    Montemurro, Filippo
    Naso, Giuseppe
    Pronzato, Paolo
    Puglisi, Fabio
    Tondini, Carlo Alberto
    FUTURE ONCOLOGY, 2020, 16 (05) : 129 - 145
12345